Can kids with eczema take less medicine? new study aims to find out
NCT ID NCT06116526
First seen Jan 12, 2026
Summary
This study looks at whether children aged 1 to 17 with well-controlled atopic dermatitis (eczema) can safely reduce their dose or stop taking dupilumab (Dupixent) without their skin condition getting worse. About 30 children who have been on dupilumab for at least a year and have had good control for the last 6 months will be randomly assigned to continue the standard dose, take a lower dose, or stop the drug. The goal is to see if de-escalation is possible while keeping eczema under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Univerisity
RECRUITINGBaltimore, Maryland, 21210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, this could show that some children with well-controlled eczema can safely take less medication or stop it altogether, reducing treatment burden and side effects.
What could go wrong
This is a small pilot study with only 30 children, so results may not apply to everyone. Some children may need to restart or increase their dose if eczema flares up.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.